Background & Aims

Patients with sickle cell disease (SCD) experience recurrent, unpredictable acute pain episodes, referred to as vaso-occlusive crises (VOCs). Pain from VOC is so severe that it is the primary reason for emergency room visits and hospitalizations. Opioids are the primary treatment for pain from VOC but are associated with many serious side effects.

The analgesic properties of inhaled nitrous oxide (N2O) are well known, however, there are substantial barriers to its use at home. Oral N2O may be an effective treatment for VOC pain at home in order to reduce hospitalizations and opioid use, particularly when taken immediately upon initiation of a VOC.

Aim of Investigation: HBI-201 is an oral liquid drug product containing N2O. HBI-201 was supplied by Hillhurst Biopharmaceuticals, Inc. Using humanized transgenic mice with SCD, we determined if oral administration of HBI-201 reduced mechanical and heat hyperalgesia following VOC produced by cold exposure in sickle mice.

Methods

Male and female Townes transgenic HbSS (sickle) and HbAA (control) mice were used. Only mice that did not exhibit baseline hyperalgesia were used. VOC was evoked by exposing mice to cold ambient temperature (10 degrees C) for 1 hour. This produces vaso-occlusion and robust mechanical and heat hyperalgesia (Khasabova et al., 2022). Mechanical hyperalgesia was defined as a decrease in paw withdrawal threshold (PWT) using calibrated von Frey monofilaments applied to the plantar surface. Heat hyperalgesia was defined as a decrease in paw withdrawal latency (PWL) in response to a radiant heat stimulus applied to the plantar hind paw. PWT and PWL were averaged for both paws. PWT and PWL were determined before and at 10 min after cold exposure. Mice then received vehicle or N2O (HBI-201) by oral gavage (4, 10 or 20 mg/kg body weight), or morphine (5 mg/kg, s.c.), and PWT and PWL were determined at various times thereafter. We also measured oral N2O-mediated analgesia in naïve C57 mice.

Results

HBI-201, but not vehicle, reduced cold-evoked mechanical and heat hyperalgesia dose-dependently. The anti-hyperalgesic effect of oral N2O peaked at approximately 90 min after administration and persisted for at least 3 hours following the highest dose. The antihyperalgesia following N2O (20 mg/kg, p.o.) was similar to that produced by morphine (5 mg/kg, s.c.). There were no obvious differences between male and female mice. N2O also produced analgesia (increased PWT and PWL) in control C57 mice that lasted for 1-2 hours.

Conclusions

The oral N2O drug HBI-201 produces antinociception and reduces hyperalgesia in a mouse model of VOC pain in SCD. N2O via HBI-201 shows promise and potential for home use to reduce hospitalization and opioid utilization in sickle patients experiencing a painful VOC. Studies are ongoing, including assessing if oral N2O reduces spontaneous and persisting pain during VOC, and if oral N2O produces side effects including reward and motor dysfunction.

References

Khasabova, I.A., Juliette, J., Rogness, V.M., Khasabov, S.G., Golovko, M.Y., Golovko, S.A., Kiven, S., Gupta, K., Belcher, J.D., Vercellotti, G.M., Seybold, V.S., and Simone, D.A. A model of painful vaso-occlusive crisis in mice with sickle cell disease. Blood, 140(16):1826-1830, 2022.

Presenting Author

Donald Simone

Poster Authors

Donald A. Simone Ph.D.

PhD

UMN

Lead Author

Ana Alves BS

University of Minnesota

Lead Author

Kaje Allen BS

University of Minnesota

Lead Author

Fuad Abdulla DVM

University of Minnesota

Lead Author

Iryna Khasabova

University of Minnesota

Lead Author

Sergey Khasabov

University of Minnesota

Lead Author

Andrew Gomperts MBA

JD

Hillhurst Biopharmaceuticals, Inc.

Lead Author

Edward Gomperts MD

Hillhurst Biopharmaceuticals, Inc.

Lead Author

John Belcher PhD

University of Minnesota

Lead Author

Gregory Vercellotti MD

University of Minnesota

Lead Author

Topics

  • Models: Acute Pain